Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells

Biomedicine and Pharmacotherapy

Volumn 61, Issue 9 SPEC. ISS., 2007, Pages 578-587

  Ho, Tik Shun ^a   Ho, Yuk Ping ^a   Wong, Wing Yin ^a   Chi Ming Chiu, Lawrence ^a   Wong, Yum Shing ^a   Eng Choon Ooi, Vincent ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

C75; Cerulenin; Melanoma

Indexed keywords

4 METHYLENE 2 OCTYL 5 OXO TETRAHYDRO FURAN 3 CARBOXYLIC ACID; C 75; CASPASE; CASPASE INHIBITOR; CERULENIN; DNA FRAGMENT; FATTY ACID SYNTHASE INHIBITOR; FLUORESCEIN ISOTHIOCYANATE; FLUOROMETHYL KETONE; LIPOCORTIN 5; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROCASPASE 3; PROPIDIUM IODIDE; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P21; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INDUCTION; FLOW CYTOMETRY; GENE DELETION; GROWTH RETARDATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

EID: 35248870232     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.08.020     Document Type: Article

References (37)

1. Alo P.L., Visca P., Marci A., Mangoni A., Botti C., and Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77 (1996) 474
2. Bull J.H., Ellison G., Patel A., Muir G., Walker M., Underwood M., et al. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 84 (2001) 1512
3. Kridel S.J., AxeIrod F., Rozenkrantz N., and Smith J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64 (2004) 2070
4. Russell A.D. Whither triclosan?. J Antimicrob Chemother 53 (2004) 693
5. Liu B., Wang Y., Fillgrove K.L., and Anderson V.E. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol 49 (2002) 187
6. Menendez J.A., Vellon L., and Lupu R. Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16 (2005) 1253
7. Omura S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthase. Bacteriol Rev 40 (1976) 681
8. Menendez J.A., Mehmi I., Atlas E., Colomer R., and Lupu R. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 24 (2004) 591
9. Heiligtag S.J., Bredehorst R., and David K.A. Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ 9 (2004) 1017
10. Pizer E.S., Wood F.D., Heine H.S., Romantsev F.E., Pasternack G.R., and Kuhajda F.P. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56 (1996) 1189
11. Pizer E.S., Thupari J., Han W.F., Pinn M.L., Chrest F.J., Frehywot G.L., et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60 (2000) 213
12. Alli P.M., Pinn M.L., Jaffee E.M., McFadden J.M., and Kuhajda F.P. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24 (2004) 39
13. Tyillianakis P.E., Kakabakos S.E., Evangelators G.P., and Ithakissios D.S. Direct colorimetric determination of solid, supported functional groups & ligands using bicinchoninic acid. Anal Biochem 219 (1994) 335
14. Pestell R.G., Albanese C., Reutens A.T., Segall J.E., Lee R.J., and Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20 (1999) 501
15. Kluger H.M., DiVito K., Berger A.J., Halaban R., Ariyan S., Camp R.L., et al. Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray study. Melanoma Res 14 (2004) 207
16. Menendez J.A., Lupu R., and Colomer R. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Perspect 18 (2005) 375
17. Shah U.S., Dhir R., Gollin S.M., Chandran U.R., Lewis D., Acquafondata M., et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol 37 (2006) 401
18. Menendez J.A., Vellon L., Mehmi I., Oza B.P., Ropero S., Colomer R., et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101 (2004) 10715
19. De Schrijver E., Brusselmans K., Heyns W., Verhoeven G., and Swinnen J.V. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63 (2003) 3799
20. Brusselmans K., De Schrijver E., Verhoeven G., and Swinnen J.V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 65 (2005) 6719
21. Mandelin II A.M., and Pope R.M. Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 11 (2007) 363
22. Qin J.Z., Xin H., Sitailo L.A., Denning M.F., and Nickoloff B.J. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 66 (2006) 9636
23. Thallinger C., Wolschek M.F., Wacheck V., Maierhofer H., Gunsberg P., Polterauer P., et al. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 120 (2003) 1081
24. Vander Heiden M.G., Li X.X., Gottleib E., Hill R.B., Thompson C.B., and Colombini M. Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane. J Biol Chem 276 (2001) 19414
25. Villedieu M., Louis M.H., Dutoit S., Brotin E., Lincet H., Duigou F., et al. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 105 (2007) 31
26. Lei X., Huang Z., Zhong M., Zhu B., Tang S., and Liao D. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells. Acta Biochim Biophys Sin 39 (2007) 344
27. Li W., Sanki A., Karim R.Z., Thompson J.F., Soon Lee C., Zhuang L., et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38 (2006) 287
28. Lee M.H., and Yang H.Y. Contributions in the domain of cancer research: negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci. 2001 (1907) 58
29. Li J.N., Gorospe M., Chrest F.J., Kumaravel T.S., Evans M.K., Han W.F., et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 61 (2001) 1493
30. Zhao W., Kridel S., Thorburn A., Kooshki M., Little J., Hebbar S., et al. Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 95 (2006) 869
31. Gao Y., Lin L.P., Zhu C.H., Chen Y., Hou Y.T., and Ding J. Growth arrest induced by C75, a fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther. 5 (2006) 978
32. Menendez J.A., Oza B.P., Atlas E., Verma V.A., Mehmi I., and Lupu R. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene 23 (2004) 4945
33. Menendez J.A., Vellon L., Colomer R., and Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 115 (2005) 19
34. Menendez J.A., Colomer R., and Lupu R. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol Rep 12 (2004) 411
35. Cummings J., Ward T.H., Ranson M., and Dive C. Apoptosis pathway-targeted drugs - from the bench to the clinic. Biochim Biophys Acta 705 (2004) 53
36. Makin G., and Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 11 (2001) S22
37. Sun S.Y., Hail Jr. N., and Lotan R. Apoptosis is a novel target for cancer chemoprevention. J Natl Cancer Inst 96 (2004) 662